BIRMINGHAM, Ala., March 27, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC), the country's largest owner and operator of inpatient rehabilitation hospitals, has named Andrew Baird as senior vice president of public policy, legislation and regulations.
Baird brings nearly 20 years of experience to his role as SVP of public policy, legislation and regulations, which includes his tenure as director of governmental affairs for the Company. Most recently, Baird served as vice president of government affairs and policy counsel of Enhabit Home Health and Hospice. In this role, he led all advocacy, government affairs and public policy matters. Prior to joining Encompass Health in 2014, he served as an associate at Christian & Barton, LLP in the firm's health care and life sciences practice.
Baird earned his bachelor's degree from Trinity College and juris doctorate degree from the University of North Carolina School of Law. He began his new role with the Company on January 29, 2024.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 160 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media Contact:
Kennedi Spurling | 205 970 5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Mark Miller | 205 970 5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$100.23 |
Daily Change: | -1.11 -1.10 |
Daily Volume: | 776,330 |
Market Cap: | US$10.090B |
November 04, 2024 October 28, 2024 August 05, 2024 July 30, 2024 July 08, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB